Live
- Kumbh Mela 2025: Essential Guide to Comfortable and Respectful Attire for Maha Kumbh
- Hyderabad Real Estate Faces Setback: Property Sales Drop 7% Year-on-Year in 2024
- Gnani’s Gen AI Solutions Revolutionising BFSI
- Trump's WHO threat sparks debate on the efficiency of global health governance
- ICC Champions Trophy 2025 Schedule: India vs Pakistan Match Set for February 23 in Dubai
- Champions Trophy 2025: Full Schedule, Match Dates, Venues, Timings, and Updates
- FRAI Urges Government to Provide Technology Platform for Kirana Stores to Stay Competitive
- Not just Gen Z, millennials too: Redditors discuss the wave of pet parenthood embraced by young Indians
- Innovation can expedite the journey to a Smoke-Free future- in focus at Technovation Abu Dhabi
- Pramod Kumar Voola: Pioneering ethical AI and innovation in healthcare technology
Natco Pharma gets EIR from FDA for Hyd facility
Highlights
Drug firm Natco Pharma on Tuesday said it has received establishment inspection report (EIR) from the US health regulator for its facility near Hyderabad.
New Delhi: Drug firm Natco Pharma on Tuesday said it has received establishment inspection report (EIR) from the US health regulator for its facility near Hyderabad.
In a BSE filing, Natco Pharma announced "successful closure of inspection" with the receipt of an establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at its active pharmaceutical ingredient (API) facility in Mekaguda Village, near Hyderabad, India.
The plant was inspected during the period August 5-9, 2019, it added. The USFDA gives EIR on closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection.
Next Story
ADVERTISEMENT
